A recent study indicated that hypoglycemic tumor microenvironment increases resistance to cytotoxic agents in GC, especially in tumor cells with an enhanced glycolysis phenotype [24]; glucose deprivation was also shown to drive the acquisition of KRAS mutations in colorectal cancer, which mediates tumor plasticity in multiple ways [25–27]. This evidence concerns the gene KRAS and neoplasm.